The latest development in health is that the US Food and Drug Administration (FDA) on August 26 approved the expanded use of automated insulin pump systems to include those with type 2 diabetes. In 2022, the FDA initially signed off on the system that automated the process of adjusting insulin delivery as needed for type 1. This makes it the first automated device to deliver insulin to people with type 2 diabetes. It is called the Omnipod 5. The FDA said the clearance "provides a new option that can automate many of these manual tasks [of tracking and managing blood sugar levels], potentially reducing the burden of living with this chronic disease," as reported in U.S.News. What Was It Like Earlier?Earlier, insulin options for people with type 2 diabetes were limited to injection with a syringe, an insulin pen or an insulin pump. These devices require the patients to administer the insulin one or more times a day and check their blood sugar levels frequently.What Does The Automated Device Do?With the new system, the wearable product provides up to three days of non-stop insulin delivery without the need to handle a needle. The Omnipod 5 works with a continuous glucose monitor that checks the blood sugar without the need for daily injections or finger pricks. The FDA has long worked with the diabetes community to ensure access to additional options and flexibilities for diabetes management," said Dr. Michelle Tarver, acting director of the FDA's Center for Devices and Radiological Health. "The FDA is committed to advancing new device innovation that can improve the health and quality of life for people living with chronic diseases that require day-to-day maintenance like diabetes."“I’ve seen firsthand how difficult it is for patients to reach their targets with injections,” Dr. Anne Peters, said the director of the University of Southern California Westside Center for Diabetes. “Omnipod 5 makes it easier for people with type 2 diabetes to take their insulin and stay in range, leading to remarkable improvements in clinical outcomes and overall quality of life.”How Was It Approved?The FDA reviewed data from a clinical study of 289 individuals who were 18 years and older with type 2 diabetes that went on for 13 weeks. The researchers discovered that the blood sugar control improved across all demographic groups of the candidates. The adverse events were generally mild to moderate and included hyperglycemia (high blood sugar), hypoglycemia (low blood sugar) and skin irritation. Why Is It A Big Step For The US?As per the US Centers for Disease Control and Prevention, about 38.4 million people are diagnosed with diabetes in the US. It is a condition where the body does not make enough use of the blood glucose to regulate the hormone insulin. With type 2 diabetes, the pancreas makes less insulin than it uses and thus the body becomes insulin resistant. FDA noted that people with diabetes 2 may also take other medications that can help their insulin secretion and improve insulin sensitivity.